KR KRX
Samsung BioLogics Co., Ltd.
South Korean contract drug maker that changed the accounting treatment of an affiliate, inflating net profit by 4.5 trillion won prior to IPO.
CORPORATE IDENTIFIERS & DOSSIER
- Entity Name: Samsung BioLogics Co., Ltd.
- Country of Domicile: KR
- Listing & Ticker: KRX (207940).
- CIK / LEI Identifier: Unregistered.
- Industry Classification: SIC 2834.
- Enforcement Episodes: 1 primary case dossier(s) in this library.
PRIMARY ENFORCEMENT CASES INVOLVING SAMSUNG BIOLOGICS CO., LTD.
1 CASE DOSSIERS| Case Title | Status | Primary Scheme | Overstatement | Total Penalties | Action Date |
|---|---|---|---|---|---|
| Samsung BioLogics: 4.5 Trillion Won Acquisition Accounting Inflation | Adjudicated | acquisition accounting abuse | $3.8B | $7.0M | September 20, 2020 |